跳至主要内容
临床试验/NCT05244018
NCT05244018已完成4 期

Outcome of High Dose Vitamin D on Prognosis of Sepsis Requiring Mechanical Ventilation; A Randomized Controlled Trial

Ain Shams University1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2022年3月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
80
试验地点
1
主要终点
Change in procalcitonin level (ng/ml) and antimicrobial peptide cathelicidin (LL37) (ng/ml) level at day 7.

研究概览

简要总结

There is a high prevalence of vitamin D deficiency in the critically ill patient population, with approximately 60% of patients found to be vitamin D deficient, (25(OH)D concentrations <20 ng/mL) and an additional 30% of patients being vitamin D insufficient, (25(OH)D = 20-30 ng/mL).Approximately 80% of sepsis/septic shock patients experience respiratory failure and require mechanical ventilation. Furthermore, several studies document that vitamin D deficiency could be associated with poor outcomes in critically ill patient.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with sepsis and required mechanical ventilation (MV) within 24 hours from ICU admission.
  • Expected to require mechanical ventilation for at least 72 hours after study entry.

排除标准

  • Age <18 years.
  • inability to obtain informed consent from the patient and/or legally authorized representative.
  • Pregnant or breastfeeding.
  • Chronic kidney diseases
  • Pancreatitis.
  • Hepatic insufficiency
  • Cases with coagulopathy
  • Moribund and not expected to survive 96 hours.
  • Ongoing shock
  • History of therapy with high dose vitamin D3 within previous 6 months.
  • History of disorders associated with hypercalcemia
  • Cancer as the cause of sepsis.
  • Subjects undergoing chemotherapy.
  • Immune compromised patients.
  • Pneumonia developed < 48 hours following intubation.
  • Patients with history of aspiration before intubation.
  • known allergy to vitamin D.

研究组 & 干预措施

Group 1(Treatment group)

Active Comparator

干预措施: Vitamin D3 tablets (Drug)

Group 2(Control group)

Active Comparator

干预措施: Vitamin D tablets (Drug)

结局指标

主要结局

Change in procalcitonin level (ng/ml) and antimicrobial peptide cathelicidin (LL37) (ng/ml) level at day 7.

时间窗: 7 days

Change in procalcitonin level (ng/ml) and antimicrobial peptide cathelicidin (LL37) (ng/ml) level at day 7.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr.Ibrahim Mamdouh Esmat

Assistant Professor of Anesthesia and Intensive Care Department, Faculty of Medicine, Ain- shams University, Cairo, Egypt.

Ain Shams University

研究点 (1)

Loading locations...

相似试验